Antiplatelet effects and pharmacodynamics of clopidogrel in cats

Journal of the American Veterinary Medical Association

Volumn 225, Issue 9, 2004, Pages 1406-1411

  Hogan, Daniel E ^a   Andrews, Dina A ^a,c   Green, Henry W ^a   Talbott, Kristen K ^a   Ward, Michael P ^a   Calloway, Betsy M ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c ANTECH DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; COLLAGEN; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; CAT; CONTROLLED STUDY; DOMESTIC ANIMAL; DRUG EFFECT; FEMALE; MALE; MOUTH MUCOSA; NONHUMAN; ORAL BLEEDING; SEROTONIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; CATS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOM ALLOCATION; SEROTONIN; TICLOPIDINE; TREATMENT OUTCOME;

ANIMALIA; FELIS CATUS;

EID: 7444266689     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2004.225.1406     Document Type: Article

References (47)

1. Harpster NK. Feline myocardial diseases. In: Kirk RW, ed. Current veterinary therapy IX. Philadelphia: WB Saunders Co, 1986;380-388.
2. Bonagura JD, Fox PR. Restrictive cardiomyopathy. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;863-867.
3. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003;17:73-83.
4. Helenski CA, Ross JN. Platelet aggregation in feline cardiomyopathy. J Vet Intern Med 1987;1:24-28.
5. Welles EG, Boudreaux MK, Crager CS, et al. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994;55:619-627.
6. Schaub RG, Meyers KM, Sande RD, et al. Inhibition of feline collateral vessel development following experimental thrombotic occlusion. Circ Res 1976;39:736-743.
7. Butler HC. An investigation into the relationship of aortic emboli to posterior paralysis in the cat. J Small Anim Pract 1971;12:141-158.
8. Olmstead ML, Butler HC. Five-hydroxytryptamine antagonists and feline aortic embolism. J Small Anim Pract 1977;18:247-259.
9. Pion PD. Feline aortic thromboemboli: t-PA thrombolysis followed by aspirin therapy and rethrombosis. Vet Clin North Am Small Anim Pract 1988; 8:262-263.
10. Laste NJ, Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 1995;31:492-500.
11. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-1295.
12. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987;34:222-262.
13. Thebault JJ, Kieffer G, Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999;25(suppl 2):3-8.
14. Thebault JJ, Kieffer G, Lowe GDO, et al. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999;25(suppl 2):9-14.
15. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1(8649):1215-1220.
16. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-507.
17. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
18. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
19. Hogan DF, Andrews DA, Talbott KK, et al. Evaluation of antiplatelet effects of ticlopidine in cats. Am J Vet Res 2004;65:327-332.
20. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
21. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996;76:939-943.
22. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54:745-750.
23. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. Drug Saf 1999;21:325-335.
24. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-1777.
25. Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am J Ther 2000;7:317-318.
26. Parker MT, Collier LL, Kier AB, et al. Oral mucosal bleeding times of normal cats and cats with Chediak-Higashi syndrome or Hageman trait (factor XII deficiency). Vet Clin Pathol 1988;17:9-12.
27. Lerner RG, Frishman WH, Mohan KT. Clopidogrel: a new antiplatelet drug. Heart Dis 2000;2:168-173.
28. Gachet C. Platelet activation by ADP: the role of ADP antagonists. Ann Med 2000;32(suppl 1):15-20.
29. Dogne JM, de Leval X, Benoit P, et al. Recent advances in antiplatelet agents. Curr Med Chem 2002;9:577-589.
30. Steinhubl SR. Antiplatelet agents in cardiology: the choice of therapy. Ann Thorac Surg 2000;70:S3-S8.
31. Bhatt DL, Chew DP Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-368.
32. Fareed J, Messmore HL. Clopidogrel. Semin Thromb Hemost 1999;25:1-84.
33. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by Clopidogrel and ticlopidine. Thromb Res 1998;92:83-89.
34. Herbert JM, Defreyn TG, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arteriosder Thromb 1993;13:1171-1179.
35. Gryglewski RJ, Dupin JP, Uracz W, et al. Thrombolysis by thienopyridines and their congeners. J Physiol Pharmacol 2000;51:683-693.
36. Dupin JP, Gryglewski RJ, Gravier D, et al. Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. J Pitysiol Pharmacol 2002;53:625-634.
37. Orford JL, Fasseas P, Brosh D, et al. Clopidogrel. Indian Heart J 2001;53:788-791.
38. Taka T, Okano E, Seki J, et al. Effects of clopidogrel on platelet activation and coagulation of non-anticoagulated rat blood under high shear stress. Haemostasis 1999;29:189-196.
39. Calverley DC, Roth GJ. Antiplatelet therapy: aspirin, ticlopidine/clopidogrel, and anti-integrin agents. Hematol Oncol Clin North Am 1998;12:1231-1249.
40. Bennett JS. Novel platelet inhibitors. Annu Rev Med 2001;52:161-184.
41. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-532.
42. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896.
43. Imhoff RK. Production of aortic occlusion resembling acute aortic embolism syndrome in cats. Nature 1961;192:979-984.
44. Yang LH, Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997;86:479-491.
45. Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000;356:269-270.
46. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998;128;541-544.
47. Boudreaux MK, Jeffers C, Lipscomb D, et al. The effect of ticlopidine on canine platelets, fibrinogen, and antithrombin III activity. J Vet Pharmacol Ther 1992;15:1-9.